{"nctId":"NCT00375713","briefTitle":"Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal速 (Levocetirizine) vs Zyrtec速 (Cetirizine) in Subjects With Dermatitis and Eczema","startDateStruct":{"date":"2005-10"},"conditions":["Dermatitis","Eczema"],"count":466,"armGroups":[{"label":"Levocetirizine","type":"EXPERIMENTAL","interventionNames":["Drug: Levocetirizine","Drug: Placebo-Cetirizine","Drug: Standard topical steroid (1% hydrocortisone) ointment"]},{"label":"Cetirizine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cetirizine","Drug: Placebo-Levocetirizine","Drug: Standard topical steroid (1% hydrocortisone) ointment"]}],"interventions":[{"name":"Levocetirizine","otherNames":["Xyzal速"]},{"name":"Cetirizine","otherNames":["Zyrtec速"]},{"name":"Placebo-Levocetirizine","otherNames":[]},{"name":"Placebo-Cetirizine","otherNames":[]},{"name":"Standard topical steroid (1% hydrocortisone) ointment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects diagnosed as having atopic dermatitis, contact dermatitis, prurigo, pruritus in the dermatitis and eczema\n* Subjects who require and agree to the concomitant use of a topical steroid preparation.\n* Subjects having a minimum level of pruritus and having used topical hydrocortisone during the run -in period\n* Written informed consent signed and dated by subject/legal guardian\n* Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method and have a negative pregnancy test.\n\nExclusion Criteria:\n\n* Subjects with a known hypersensitivity to cetirizine or levocetirizine\n* Any clinically significant condition that might interfere with the treatment evaluation, both for efficacy and safety\n* Have used forbidden concomitant medications or having not respected adequate wash-out periods as defined by the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score).","description":"A participant is a responder if the pruritus severity score is assessed as mild or none, otherwise it is a non-responder. The responder status is defined at day 14, except if the investigator assessed the subject as a responder at day 7. The Pruritus Score is in general defined as: 3 for Severe, 2 for Moderate, 1 for Mild and 0 for None.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Mean Pruritus Severity Score at Endpoint During the 14 Day Treatment Period","description":"The Pruritus Score Scale ranges from 0 to 3 (3 for Severe, 2 for Moderate, 1 for Mild and 0 for None). Endpoint is at visit 4 on day 14 or at an earlier timepoint at study completion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"0.05"},{"groupId":"OG001","value":"1.21","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Duration of Pruritus (Stated in Categories) at Endpoint During the 14 Day Treatment Period","description":"Duration of pruritus was categorized as follows: 3 if \\> 6 hours/24hr, 2 if 1 to 6 hours/24hr, 1 if less than 1 hour/24hr, and 0 if No pruritus. The endpoint is visit 4 on day 14 or at an earlier time point at study completion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"0.05"},{"groupId":"OG001","value":"2.20","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Global Improvement at Endpoint During the 14 Day Treatment Period","description":"Global improvement is measured on an ordered nominal scale ranging from marked improvement to exacerbation (see categories in the table). The endpoint is visit 4 on day 14 or at an earlier time point at study completion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":209},"commonTop":["Rhinitis"]}}}